
Revvity Inc (RVTY) Stock Forecast & Price Target
Revvity Inc (RVTY) Analyst Ratings
Bulls say
Revvity's positive outlook is supported by its strong growth trajectory in both its life sciences and diagnostics segments, highlighted by the transition from TST to IGRA, which is expected to contribute to annual market growth. The company's financial profile has improved significantly through strategic acquisitions such as BioLegend and EUROIMMUN, which bolster its leading positions in reagents and immunodiagnostics, while also enhancing cross-selling opportunities across its portfolio. Additionally, the integration of a high-margin software solution, Signals, contributes recurring revenue and operating leverage, further supporting the company’s higher profitability potential and market penetration strategies.
Bears say
The financial outlook for Revvity appears unfavorable due to significant challenges in its China segment, particularly in Immunodiagnostics, where revenues are projected to decline substantially, potentially falling below 5% of total revenues by 2026. Additionally, broader economic conditions and industry funding cuts are likely to impact customer demand negatively, leading to reduced growth and market share for the company's products and services. Furthermore, macroeconomic factors such as product shortages, transit delays, and labor shortages may disrupt Revvity's supply chain, exacerbating the company's performance issues.
This aggregate rating is based on analysts' research of Revvity Inc and is not a guaranteed prediction by Public.com or investment advice.
Revvity Inc (RVTY) Analyst Forecast & Price Prediction
Start investing in Revvity Inc (RVTY)
Order type
Buy in
Order amount
Est. shares
0 shares